3SBIO's stock price plummeted 5.09% during intraday trading on Thursday, reflecting a significant sell-off in the market.

The sharp decline is attributed to two key negative developments. First, the Hong Kong Stock Exchange disclosed that the IPO application for the company's subsidiary, Mandi International, has automatically expired after failing to complete its listing hearing within the required timeframe. Second, 3SBIO announced plans to replace its auditor of over 15 years, Ernst & Young, with KPMG, a move that has introduced additional uncertainty during a period of fragile investor confidence.

This downturn persists despite the company's substantial cash reserves from recent major deals. The current market capitalization remains below the perceived value of its assets, contributing to shareholder frustration over the lack of significant share buyback initiatives to support the stock price.